DVA

DaVita Inc presents a distinctive financial profile among dialysis providers, with systematic screening highlighting an exceptional ROE of 181.22% that substantially exceeds typical healthcare service metrics. This extraordinary return stems from minimal book value per share of $1.50 combined with earnings power of $10.77 per share, creating the elevated P/B ratio of 101.25 that characterizes asset-light business models with significant intangible value.

The company's profitability metrics demonstrate operational consistency across multiple dimensions. Net margin of 5.65% and operating margin of 14.98% reflect the regulated nature of dialysis reimbursement, while gross margin of 32.45% indicates stable clinical economics. Revenue growth of 6.68% year-over-year aligns with demographic trends in chronic kidney disease prevalence, supported by corresponding EPS expansion of 6.61%.

Fundamental screening identifies several strengths:

• Beta of 0.89 positions the equity as moderately defensive within healthcare services
• Current ratio of 1.29 provides adequate short-term liquidity for operational requirements
• Trading near the upper bound of its 52-week range ($101.00–$202.69) reflects sustained institutional accumulation

The primary risk factor centers on leverage, with debt-to-equity of 77.99 representing substantial balance sheet obligations relative to equity base. This capital structure magnifies both ROE calculations and financial risk during reimbursement pressure cycles. Additionally, the P/E of 16.41 appears reasonable but offers limited multiple expansion potential given single-digit growth rates.

Relative to diversified health peers CVS and CI, the model indicates DVA operates in a more specialized niche with higher operating leverage and concentration risk in kidney care economics.